Investing in Abridge: We’re thrilled to announce that Redpoint is co-leading Abridge’s $150M Series C. Abridge is the leading generative AI company for clinical documentation. Healthtech is a difficult space. There remains a large gap between the health system we want and what we have. Companies often face trade-offs between full impact and viable business models. Sales cycles are long. It’s often not clear just how helpful some technology really is.
Feb. 23, 2024, 3:15 p.m.
Mark Cuban on Disrupting PBMs, Staying Curious and Using AI to Avoid NBA Fines: On our latest Vital Signs episode, we talked about problems in pharmacy with Mark Cuban, founder of The Mark Cuban Cost Plus Drug Company. Mark talked about why he decided to get into healthcare, what’s broken about the system, staying curious as a founder, what’s most over/underhyped about AI and more.
Oct. 24, 2023, 4 p.m.
The Future of AI In Medical Diagnosis: In Conversation With PathAI CEO Dr. Andy Beck: For our second crossover episode between Vital Signs and Unsupervised Learning we explored the impact of AI on pathology with PathAI Co-Founder and CEO Dr. Andy Beck. Andy talked about his journey studying both pathology and computer science throughout his MD and PhD programs, as well as how advances in computer vision created the opportunity to start PathAI (last valued at close to $1B). We also hit on why Pat
July 27, 2023, 4:18 p.m.
How Insitro Is Using AI to Create Better Medicines: In Conversation With Daphne Koller: On our first crossover episode between Unsupervised Learning and Vital Signs, we dove deep into the world of using AI in drug development with Insitro CEO Daphne Koller. See the full episode below! We sat down with Daphne to discuss how Insitro distinguishes itself from other AI drug discovery companies, where ML can drive the most impact in drug development, if foundation models transform drug discovery and
June 16, 2023, 12:07 p.m.
